Blog Archive
-
▼
2008
(233)
-
▼
May
(27)
- Pipex Pharmaceuticals : Oral Flupirtine Patent Est...
- Daiichi Sankyo : AZOR Reduces Blood Pressure in Di...
- DiaMedica : pre-IND FDA Guidance on DM-71
- ALR Technologies : ECHO of Alabama Employer Coalit...
- AtheroGenics : ARISE Trial Results Published in Th...
- Daiichi Sankyo : Welchol, Combined With Metformin ...
- DiaMedica : Enrollment in Phase II Clinical Trial ...
- Allon : potential of AL-309 as a new neuropathy tr...
- Entelos : Agreement with Lilly
- FivePrime and Pfizer : Diabetes Collaboration
- Diasome Pharmaceuticals : at the 68th Annual Ameri...
- Phenomix : PHX1149 Phase 2b Clinical Trial Results...
- Aradigm : Data Showing No Occurrence of Primary Lu...
- MicroIslet : Collaboration With DiaKine Intended T...
- CytRx : Discovery of Novel Compounds that Amplify ...
- RegeneRx : Ophthalmic Patent in Hong Kong
- Elixir Pharmaceuticals : Issuance of SIRT Patent C...
- OXiGENE : Active Metabolite of ZYBRESTAT Improves...
- Incyte : Positive Clinical Progress
- Merck's JANUMET (sitagliptin/metformin HCl) Recomm...
- Pfizer : Research Consortium to Expand Understandi...
- NOVAGALI : First Patient in U.S. Phase I Clinical ...
- Solianis Monitoring : Non-Invasive Glucose Monitoring
- Nektar Terminates All Negotiations With Potential ...
- CureDM : Diabetes Therapy Major Development Achieved
- Biocon Limited : Phase IIa Clinical Trials for IN105
- Toumaz Technology and Consortium Partners : Major ...
-
▼
May
(27)
Monday, May 5, 2008
Toumaz Technology and Consortium Partners : Major EU Funding To Develop Personal Blood Glucose Predictor For Diabetes Patients
10 April 2008 – Toumaz Technology Limited, the leading provider of ultra-low power wireless infrastructure for body monitoring solutions, announces its participation in a major collaborative research project that has been granted 7.1 million Euros to develop a unique personalised blood glucose prediction tool aimed at improving the lives of millions of diabetes patients. The grant award, made under the Seventh Framework Programme (FP7) of the European Community, will fund a four-year research and development project into the “DIAdvisor™” portable glucose prediction system, that will utilise Toumaz’s breakthrough Sensium™ wireless body monitoring technology. The large-scale project is being coordinated by Novo Nordisk A/S, a world leader in diabetes care, and will be delivered by a consortium of 13 medical, industrial and academic partners, including the European region of the International Diabetes Federation (IDF)...Toumaz Technology 's Press Release -
Libellés :
Blood Glucose Monitoring,
Toumaz Technology